Jessica Fye
Stock Analyst at JP Morgan
(3.69)
# 815
Out of 4,711 analysts
177
Total ratings
50.44%
Success rate
6.52%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintains: Underweight | $59 → $45 | $39.39 | +14.24% | 11 | Nov 26, 2024 | |
| BNTX BioNTech SE | Maintains: Neutral | $124 → $122 | $113.08 | +7.89% | 10 | Nov 26, 2024 | |
| INSM Insmed | Maintains: Overweight | $74 → $83 | $70.44 | +17.83% | 6 | Nov 22, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $510 → $503 | $397.27 | +26.61% | 6 | Nov 5, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Overweight | $81 → $89 | $83.45 | +6.65% | 7 | Nov 4, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $110 → $109 | $65.66 | +66.01% | 3 | Oct 30, 2024 | |
| INCY Incyte | Maintains: Neutral | $65 → $71 | $68.84 | +3.14% | 5 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Neutral | $32 → $26 | $29.71 | -12.49% | 6 | Oct 25, 2024 | |
| ASND Ascendis Pharma | Maintains: Overweight | $180 → $174 | $136.38 | +27.58% | 7 | Oct 23, 2024 | |
| BGNE BeiGene | Maintains: Overweight | $200 → $235 | $176.50 | +33.14% | 4 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $28 | $21.45 | +30.54% | 4 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $20.36 | +47.35% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $52 → $57 | $46.96 | +21.38% | 11 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $55 | $35.63 | +54.36% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $248 → $280 | $245.44 | +14.08% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $190 → $202 | $122.97 | +64.27% | 3 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $66 | $28.33 | +133.01% | 4 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $54 | $53.60 | +0.75% | 5 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $39 | $41.51 | -6.05% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $300 | $359.58 | -16.57% | 14 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $11.68 | +11.30% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $30.80 | -44.81% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $0.93 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $8.10 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $2.19 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $0.46 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $10 | $7.57 | +32.10% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $76 | $34.08 | +123.00% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $17 → $20 | $0.42 | +4,632.61% | 2 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.05 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.03 | +2,035.92% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $0.71 | +879.43% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $27 | $15.52 | +73.97% | 5 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.60 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.70 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.99 | - | 4 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.28 | - | 1 | Feb 8, 2018 |
Moderna
Nov 26, 2024
Maintains: Underweight
Price Target: $59 → $45
Current: $39.39
Upside: +14.24%
BioNTech SE
Nov 26, 2024
Maintains: Neutral
Price Target: $124 → $122
Current: $113.08
Upside: +7.89%
Insmed
Nov 22, 2024
Maintains: Overweight
Price Target: $74 → $83
Current: $70.44
Upside: +17.83%
Vertex Pharmaceuticals
Nov 5, 2024
Maintains: Overweight
Price Target: $510 → $503
Current: $397.27
Upside: +26.61%
Intra-Cellular Therapies
Nov 4, 2024
Maintains: Overweight
Price Target: $81 → $89
Current: $83.45
Upside: +6.65%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Overweight
Price Target: $110 → $109
Current: $65.66
Upside: +66.01%
Incyte
Oct 30, 2024
Maintains: Neutral
Price Target: $65 → $71
Current: $68.84
Upside: +3.14%
Alkermes
Oct 25, 2024
Maintains: Neutral
Price Target: $32 → $26
Current: $29.71
Upside: -12.49%
Ascendis Pharma
Oct 23, 2024
Maintains: Overweight
Price Target: $180 → $174
Current: $136.38
Upside: +27.58%
BeiGene
Oct 22, 2024
Maintains: Overweight
Price Target: $200 → $235
Current: $176.50
Upside: +33.14%
Oct 11, 2024
Maintains: Overweight
Price Target: $29 → $28
Current: $21.45
Upside: +30.54%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $20.36
Upside: +47.35%
Sep 19, 2024
Downgrades: Neutral
Price Target: $52 → $57
Current: $46.96
Upside: +21.38%
Aug 26, 2024
Maintains: Neutral
Price Target: $50 → $55
Current: $35.63
Upside: +54.36%
Aug 26, 2024
Maintains: Neutral
Price Target: $248 → $280
Current: $245.44
Upside: +14.08%
Aug 19, 2024
Maintains: Overweight
Price Target: $190 → $202
Current: $122.97
Upside: +64.27%
Jul 10, 2024
Maintains: Overweight
Price Target: $70 → $66
Current: $28.33
Upside: +133.01%
Jul 9, 2024
Maintains: Overweight
Price Target: $47 → $54
Current: $53.60
Upside: +0.75%
Jun 18, 2024
Maintains: Overweight
Price Target: $31 → $39
Current: $41.51
Upside: -6.05%
May 21, 2024
Maintains: Overweight
Price Target: $280 → $300
Current: $359.58
Upside: -16.57%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $11.68
Upside: +11.30%
Mar 19, 2024
Maintains: Neutral
Price Target: $15 → $17
Current: $30.80
Upside: -44.81%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $0.93
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $8.10
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $2.19
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $0.46
Upside: -
Nov 20, 2023
Reinstates: Overweight
Price Target: $10
Current: $7.57
Upside: +32.10%
Apr 19, 2023
Maintains: Overweight
Price Target: $65 → $76
Current: $34.08
Upside: +123.00%
Mar 8, 2022
Upgrades: Overweight
Price Target: $17 → $20
Current: $0.42
Upside: +4,632.61%
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $3.05
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $1.03
Upside: +2,035.92%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $0.71
Upside: +879.43%
May 12, 2020
Maintains: Overweight
Price Target: $32 → $27
Current: $15.52
Upside: +73.97%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $1.60
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $8.70
Upside: -
Feb 14, 2018
Downgrades: Underweight
Price Target: n/a
Current: $2.99
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $6.28
Upside: -